title: Cost-Effectiveness Analysis of Panitumumab Plus Mfolfox6 Versus Bevacizumab Plus Mfolfox6 for First-Line Treatment of Patients with Wild-Type Ras Metastatic Colorectal Cancer.
authors.affiliation: RTI Health Solutions, Research Triangle Park, NC, USA.
authors.forename: C N
authors.initials: CN
authors.lastname: Graham
authors.affiliation: Amgen (Europe) GmbH, Zug, Switzerland.
authors.forename: G
authors.initials: G
authors.lastname: Hechmati
authors.affiliation: Amgen (Europe) GmbH, Zug, Switzerland.
authors.forename: J
authors.initials: J
authors.lastname: Hjelmgren
authors.affiliation: Amgen France SAS, Neuilly-sur-Seine, France.
authors.forename: F
authors.initials: F
authors.lastname: De Liège
authors.affiliation: Amgen France SAS, Neuilly-sur-Seine, France.
authors.forename: J
authors.initials: J
authors.lastname: Lanier
authors.affiliation: Amgen France SAS, Neuilly-sur-Seine, France.
authors.forename: A
authors.initials: A
authors.lastname: Knoof
authors.affiliation: RTI Health Solutions, Research Triangle Park, NC, USA.
authors.forename: H
authors.initials: H
authors.lastname: Knox
authors.affiliation: Amgen, Inc., Thousand Oaks, CA, USA.
authors.forename: B
authors.initials: B
authors.lastname: Barber
authors.affiliation: ESSEC Business School, Cergy-Pontoise, France.
authors.forename: G
authors.initials: G
authors.lastname: de Pouvourville